| langue originale | Anglais |
|---|---|
| Pages (de - à) | 2422-2424 |
| Nombre de pages | 3 |
| journal | Leukemia |
| Volume | 28 |
| Numéro de publication | 12 |
| Les DOIs | |
| état | Publié - 11 déc. 2014 |
Accès au document
Autres fichiers et liens
Contient cette citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Dans: Leukemia, Vol 28, Numéro 12, 11.12.2014, p. 2422-2424.
Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs
TY - JOUR
T1 - Early death in acute promyelocytic leukemia (APL) in French centers
T2 - A multicenter study in 399 patients
AU - Rahmé, R.
AU - Thomas, X.
AU - Recher, C.
AU - Vey, N.
AU - Delaunay, J.
AU - Deconinck, E.
AU - Hirsch, P.
AU - Bordessoule, D.
AU - Micol, J. B.
AU - Stamatoullas, A.
AU - Mariette, C.
AU - Pautas, C.
AU - Bories, P.
AU - Marolleau, J. P.
AU - Hunault-Berger, M.
AU - Fegueux, N.
AU - Raffoux, E.
AU - Dombret, H.
AU - Degos, L.
AU - Fenaux, P.
AU - Adès, L.
N1 - Funding Information: Peggy Brenner, a science editor supported by the University of Arkansas for Medical Sciences, provided editorial assistance to the authors during preparation of this manuscript. This manuscript was supported by a grant from the National Institutes of Health (P01CA055819). Funding Information: BB has received research funding from Celgene and Millennium, is a consultant to Celgene and Millennium, and is a co-inventor on patents and patent applications related to use of GEP in cancer medicine that have been licensed to Myeloma Health, LLC. SZU is a consultant to Celgene, Millennium and Onyx. He has received research funding from Onyx and Celgene, and speaking honoraria from Celgene. The remaining authors declare no conflict of interest. Funding Information: Medical writing assistance was provided by Susanna Mac of Amgen. Funding for these analyses was provided by Amgen. Funding Information: SZU is a consultant to Celgene, Millennium, Onyx and Sanofi. He has received research funding from ArrayBioPharma, Celgene, Onyx, Janssen, Pharmacyclics, and speaking honoraria from Celgene, Millennium and Onyx. BB has received research funding from Celgene and Novartis. He is a consultant to Celgene and Genzyme and has received speaking honoraria from Celgene and Millennium. BB is a co-inventor on patents and patent applications related to use of GEP in cancer medicine. Funding Information: UP has received honoraria from Amgen, GlaxoSmithKline (GSK), Celgene and Novartis. MAS is a member of advisory boards for Amgen and Celgene, and a speaker for Celgene. HK has research grants from Amgen. AG is a member of advisory boards and a speaker for Amgen and GSK. GJM has been a member of advisory boards and speakers bureau for Amgen, Novartis, GSK and Celgene, received research funding from Celgene and has been a consultant for GSK. CJ and ASY are employees of and stockholders in Amgen. PF has received honoraria and research grants from Amgen, Celgene, Janssen Roche, GSK and Novartis. Funding Information: This work was supported by NIH/NCI grant CA134458 to T Skorski. Funding Information: RF has received a patent for the prognostication of MM based on genetic categorization of the disease. He has received consulting fees from Medtronic, Otsuka, Celgene, Genzyme, BMS, Lilly, Onyx, Binding Site, Millenium and AMGEN. He also has sponsored research from Cylene and Onyx. TS was supported by fundings from Hospira, Genentech, Glaxo-Smith-Kline, Jannsen, Celgene and Cephalon. The remaining authors declare no conflcit of interest. Funding Information: Technical assistance was provided by the Alvin J. Siteman Cancer Center Tissue Procurement Core, the High Speed Cell Sorter Core, and the Molecular and Genomic Analysis Core at Washington University School of Medicine and Barnes-Jewish Hospital in St Louis, MO, which are all supported by the National Cancer Institute Cancer Center Support Grant P30CA91842. This work was supported by National Institutes of Health grant R01CA162086 (TJL), PO1CA101937 (TJL), K08HL116605 (JMK) and the Barnes Jewish Hospital Foundation (TJL), as well as the Doris Duke Charitable Foundation to Washington University (SMS, Clinical Research Fellow). Funding Information: Professor Robert Peter Gale kindly reviewed the typescript. The work was supported by the National Natural Science Foundation of China (81370638 and 81230013), the National Clinical Priority Specialty, the Beijing Municipal Science and Technology Program (grant no. Z141100000214011), and Peking University People’s Hospital Research and Development Funds (RDB2012-23). Funding Information: EB is a recipient of the Marriott Specialized Workforce Development Awards in Individualized Medicine and the Henry Predolin Foundation Career Development Award. This work was supported by the Henry Predolin Foundation and grant NIH-CA95241. Funding Information: We thank P Jouany, S Katsahian and V Millul for study management, C Pautas and Y Hicheri for clinical care and E Atti and T Berthy for technical assistance (all in Assistance Publique-Hôpitaux de Paris, France). The study was sponsored and monitored by the Regional Clinical Research Office, Paris and supported by a grant from the Programme Hospitalier de Recherche Clinique (PHRC ID, P 010506) and recurrent funding from the Centers for Clinical Investigation in Biotherapy from the Henri Mondor and Pitié-Salpêtrière hospitals. The sponsors had no role in study design, data analysis, data interpretation or writing of the report.
PY - 2014/12/11
Y1 - 2014/12/11
UR - http://www.scopus.com/inward/record.url?scp=84925285818&partnerID=8YFLogxK
U2 - 10.1038/leu.2014.240
DO - 10.1038/leu.2014.240
M3 - Letter
C2 - 25142818
AN - SCOPUS:84925285818
SN - 0887-6924
VL - 28
SP - 2422
EP - 2424
JO - Leukemia
JF - Leukemia
IS - 12
ER -